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Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disease and 
the most treatable. Treatment of PD is symptomatic and generally focuses on the   replacement or 
augmentation of levodopa. A number of options are available for treatment, both in monotherapy 
of early PD and to treat complications of advanced PD. This review focuses on rasagiline and 
selegiline, two medications that belong to a class of antiparkinsonian drugs called monoamine 
oxidase B (MAO-B) inhibitors. Topics covered in the review include mechanism of action, 
efficacy in early and advanced PD, effects on disability, the controversy regarding disease 
modification, safety, and patient preference for MAO-B inhibitors.
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Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease and 
the most treatable. PD affects more than one million people in the US, including 1% 
of the population older than 55 years.1 The diagnosis of PD is clinical, based on the 
presence of bradykinesia plus rigidity, tremor, or postural instability, as well as a   typical 
history. Once the diagnosis of PD is made, symptomatic treatment may be started with 
a variety of agents. Treatment of PD generally focuses on the   replacement or augmen-
tation of levodopa. The most potent first-line agents are the dopamine agonists and 
levodopa.2 For patients who require only mild symptomatic benefit or who prefer a 
simpler treatment regimen, monoamine oxidase B (MAO-B) inhibitors are a   reasonable 
first choice for treatment.2 The MAO-B inhibitors approved for use in PD include 
selegiline (Eldepryl®, Zelapar®), and rasagiline (Azilect®). As PD progresses, motor 
complications, including “wearing off ”, may occur. “Wearing off ” is a   phenomenon 
characterized by periods of decreasing effectiveness of medication, leading up to 
the next dose. MAO-B inhibitors, in addition to their usefulness as first-line therapy, 
may also be used to lessen the degree of “wearing off ” in advanced PD.3 This review 
will examine the role of MAO-B inhibitors in PD, focusing on mechanism of action, 
efficacy, safety, and patient preferences.
Mechanism of action of MAO-B inhibitors
Monoamines are a subset of weakly basic organic compounds containing a nitrogen 
group. The monoamines that are important in neurotransmission include dopamine, 
norepinephrine, and 5-hydroxytryptamine.4 Monoamines are catabolized by an Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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intracellular enzyme called monoamine oxidase, which is 
located in the mitochondrial membrane.4,5 MAO-B is the 
major metabolic step for changing active dopamine to its 
inactive catabolites, 3,4-dihydroxyphenylacetic acid and 
  homovanillic acid. MAO-B is the subtype of MAO inhibitor 
that is primarily found in the brain, accounting for 70%–80% 
of MAO in the brain.5,6 The MAO-B inhibitors selegiline and 
rasagiline are both selective and at commonly used PD doses 
do not have significant effects on MAO-A. Both selegiline 
and rasagiline bind irreversibly to MAO-B.5,7 Selegiline 
forms a covalent bond with MAO, leading to an irrevers-
ible effect that is limited by the tissue half-life of selegiline 
(2–10 days).5 Like selegiline, the binding of rasagiline to 
MAO is irreversible, but its pharmacodynamic effect is not. 
Because the turnover time of MAO-B is relatively short 
(6–30 days in animal models), even irreversible inhibition 
does not lead to a permanent effect.5
The antiparkinsonian effect of MAO-B inhibitors is 
  primarily attributed to the inhibition of MAO-B, which 
decreases the rate of turnover of striatal dopamine.8 For a 
patient with early PD who has depressed levels of striatal 
dopamine, the elevation of endogenous dopamine that 
occurs with MAO-B inhibitors leads to a mild   symptomatic 
  benefit.9 For patients with advanced PD who are   experiencing 
  “wearing off ”, the principle is essentially the same. 
By   blocking the   breakdown of dopamine produced from 
  exogenous levodopa, the   effectiveness of the exogenous 
levodopa may be extended. The primary difference between 
early and advanced patients is that when used as monotherapy 
for early PD, MAO-B inhibitors are primarily acting on 
endogenous dopamine, whereas those with advanced PD 
and combination therapy are deriving benefits from MAO-B 
inhibition of catabolism of exogenous dopamine.
Efficacy of MAO-B inhibitors
Clinically important difference
Efficacy data in trials of MAO-B inhibitors must be examined 
in light of their indication. In early PD, efficacy has been 
determined by change in the Unified Parkinson’s Disease 
Rating Scale (UPDRS)10 or by delay in the time to initiation 
of dopaminergic therapy. The UPDRS is a widely used scale 
with four sections. Part I assesses mentation, behavior, and 
mood. Part II assesses activities of daily living (ADL). Part 
III is the motor examination. Part IV assesses   complications 
of therapy. The total scale comprises 199 points, with the 
motor examination accounting for 108 points. When using the 
UPDRS as a measure of efficacy for a symptomatic therapy, 
it is imperative to consider what is clinically meaningful, 
not just statistically significant. The clinically important 
difference (CID) on the UPDRS has been determined using 
an anchor-based analysis that ties changes in the UPDRS to 
changes in patient-centric measures of quality of life (QOL) 
and disability.11 A minimal CID requires a change in the total 
UPDRS (T-UPDRS) of 4.3 points or 2.5 points on the motor 
UPDRS (M-UPDRS). A moderate CID requires a change in 
the T-UPDRS of 9.1 points or 5.2 points on the M-UPDRS. A 
large CID requires a change in the T-UPDRS of 17.1 points 
or 10.8 points on the M-UPDRS.11 In advanced PD, efficacy 
is defined as a reduction in “off ” time or an increase in “on” 
time. “Off ” time consists of that period where medication 
effectiveness is reduced or absent, manifested clinically by 
increased tremor, rigidity, or slowness. In contrast, “on” 
time is the time during which antiparkinsonian medication is 
producing a beneficial clinical response. In clinical practice, 
this is generally measured through the clinical interview, but 
in clinical trials it can also be measured by Part IV of the 
UPDRS or through the use of a standardized diary.12
Symptomatic therapy in early  
Parkinson’s disease
Selegiline has been demonstrated in two large, randomized, 
double-blinded trials to provide a symptomatic benefit when 
used as monotherapy.13,14 When compared with placebo, 
there is an improvement of 2.7 points in the T-UPDRS and 
1.5 points in the M-UPDRS.14 Additionally, selegiline delays 
the need to initiate therapy with levodopa. In the largest study 
to date, DATATOP (Deprenyl and Tocopherol   Antioxidative 
Therapy of Parkinsonism), selegiline delayed the need for 
treatment with levodopa by almost 9 months.13 Smaller 
studies have found similar, though less dramatic, benefits 
with a 4- to 7-month delay before the need for levodopa 
treatment.14–16 An additional finding from these studies is that 
patients taking selegiline require less levodopa once   treatment 
with levodopa is required.13,16 Zydis selegiline (Zelapar®) is 
an orally disintegrating formulation that has been proven 
to have equivalent efficacy to oral tablets of   selegiline and 
represents an alternative route of   administration that may be 
beneficial for certain patients.17
Like selegiline, rasagiline has also been proven to provide 
a modest symptomatic benefit when used as   monotherapy in 
patients with early PD. The TEMPO (Rasagiline   Mesylate 
[TVP-1012] in Early Monotherapy for Parkinson’s   Disease Out-
patients) and ADAGIO (Attentuation of Disease   Progression 
with Azilect Given Once Daily) trials both demonstrated a 
clear symptomatic benefit of rasagiline.18,19 Each trial recruited 
patients with early PD who were naïve to antiparkinsonian Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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therapy. When compared with placebo,   rasagiline once daily 
at a dose of 1 mg improved the   T-UPDRS by 3–4.2 points and 
the M-UPDRS by 2.7 points.18,20 Unlike the early selegiline 
trials, rasagiline failed to demonstrate a decreased need for 
levodopa.18 The changes seen in disease severity are in the 
range of what can be considered a minimal CID.
Symptomatic therapy in advanced 
Parkinson’s disease
In addition to their use as monotherapy for early PD, MAO-B 
inhibitors may be used as adjunctive therapy in patients with 
moderate to advanced PD who are experiencing motor fluctua-
tions, specifically the “wearing off ” phenomenon. The goal of 
therapy in advanced PD is to provide a smoother response to 
levodopa. In patients whose dopaminergic medication loses 
effectiveness before the next dose is due, options for treating 
“wearing off ” include more frequent dosing of levodopa or 
adding an adjunct medication. The adjuncts that may be added 
in this case include catechol-O-methyl transferase inhibitors, 
dopamine agonists, amantadine, and MAO-B inhibitors.3 
Selegiline and rasagiline, when used in advanced PD with 
motor fluctuations, both reduce “off ” time.
Selegiline has been studied in double-blind studies in 
advanced PD and been shown to improve “wearing off ”.21–24 
The amount of time spent in the “off ” state may be reduced by 
as much as 2.2 hours per day (versus a 0.6-hour   reduction in 
the placebo group).24 Many patients may experience a wors-
ening of dyskinesias after starting treatment with selegiline, 
and in this situation the recommended course of action is to 
decrease the dose of levodopa.23 Whether or not selegiline 
improves the quality of the “on” time experienced by patients 
is debatable, with some studies showing no benefit to quality 
of “on” time,23 and others reporting more than 1 additional 
hour per day of dyskinesia-free “on” time.24 In addition to 
its effects on reduction of “off ” time, selegiline may lead 
to improvement in other aspects of advanced PD, such 
as   dysarthria, hypomimia, sialorrhea, and freezing of gait 
(FOG).23,25 The severity of “off ” time in patients treated with 
selegiline may also be reduced.26
Like selegiline, rasagiline is useful for amelioration of 
“wearing off ” in advanced PD.3 Two large, multicenter 
trials have shown that rasagiline reduces “off ” time by 
1.18–1.85 hours.27,28 In the PRESTO trial (A Randomized 
Placebo-controlled Trial of Rasagiline in Levodopa-treated 
Patients with Parkinsons Disease and Motor Fluctuations), 472 
patients with a minimum “off ” time of 2.5 hours per day were 
followed for 26 weeks. At the clinical dose of rasagiline most 
commonly used (1 mg), “off ” time was reduced by 1.85 hours 
(versus 0.91 hours for placebo). A statistically significant 
increase in “on” time with   troublesome dyskinesias occurred 
in the group randomized to rasagiline.27 In the LARGO 
trial (Lasting effect in Adjunct therapy with   Rasagiline 
Given Once Daily), 687 participants were   randomized to 
placebo,   rasagiline, or entacapone. The   primary outcome of 
change in “off ” time showed that   rasagiline (−1.18 hours) 
and   entacapone (−1.20 hours) had roughly equivalent and 
  beneficial effects compared with placebo (−0.4 hours).28 
One feature that   differentiated   entacapone from rasagiline 
was   disease severity in the “off ” state, where rasagiline was 
superior to entacapone or   placebo.28 Unlike in the PRESTO 
trial, there was no increase in troublesome dyskinesias in 
the LARGO trial. There was a small,   statistically significant 
reduction in daily levodopa dose in both of the active treat-
ment arms (−24 mg per day in the rasagiline arm; −19 mg 
per day in the entacapone arm).28 A preplanned auxiliary 
study of LARGO evaluated FOG using the Freezing of Gait 
Questionnaire and demonstrated that subjects taking rasagiline 
had less FOG than those   taking placebo.28
Disability
In addition to their effects on disease severity, MAO-B 
  inhibitors may improve measures of disability in PD. The 
literature regarding MAO-B inhibitors and disability is 
  complicated, in part because many studies have used the 
term “disability” interchangeably with disease severity. 
MAO-B inhibitors appear to reduce disability compared 
with placebo; what is unclear is whether or not they pro-
vide any additional benefit beyond other antiparkinsonian 
agents. Although the two are certainly related, disability 
and disease severity are distinct entities.29 Disability refers 
to the decrease or loss of ability due to an impairment to 
accomplish a task.29 Trials of MAO-B inhibitors that have 
included dedicated disability scales contain mixed results. 
In the LARGO trial, even in the “off ” state, rasagiline led 
to a significant improvement on the Schwab and England 
Activities of Daily Living Scale, a scale that estimates the 
ability of PD patients to carry out a number of ADLs.28,30 
Examining the UPDRS Part II ADL subscale, most tri-
als of MAO-B inhibitors demonstrate benefit, including 
DATATOP, TEMPO, and ADAGIO in early PD, as well as 
PRESTO and LARGO in advanced PD.13,18,20,27,28 Another 
measure of disability, the Columbia University Disability 
Scale, showed benefit in a small, 12-week crossover study 
of subjects receiving selegiline for advanced PD.31 Although 
shorter trials of MAO-B inhibitors indicate an improve-
ment in disability as measured by the UPDRS Part II ADL Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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subscale, two longer treatment trials of selegiline either 
showed only trends toward improvement on the UPDRS 
Part II ADL subscale32 or no difference in disability on 
two separate disability scales (Webster   Disability Scale33 
and Northwestern University Disability Scale)34 in patients 
treated with selegiline plus carbidopa/levodopa versus car-
bidopa/levodopa alone.35
Disease modification
Both selegiline and rasagiline have preclinical   neuroprotective 
effects. They prevent apoptosis through upregulation of Bcl-2 
and Bcl-XL (antiapoptotic proteins), nerve growth factor, 
brain-derived neurotrophic factor, ciliary neurotrophic 
factor, glial-derived neurotrophic factor, glutathione, and 
other antioxidants and trophic factors.36–41 Selegiline and 
rasagiline both specifically protect dopaminergic neurons 
in culture from salsolinol, a neurotoxin.42–45 Additionally, 
rasagiline is neuroprotective in primate 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine and rodent 6-hydroxydopamine 
models of parkinsonism.46,47 Selegiline and rasagiline are both 
protective in rodent brain ischemia models.48,49 The putative 
neuroprotective benefits of both agents are   separate from 
the MAO-B inhibition. Due to the abundance of   preclinical 
work, there has been considerable interest in these agents’ 
  potential as neuroprotective therapies for PD. When 
  interpreting results from these trials, it is worthwhile to note 
that the   clinical effects seen are best referred to as disease 
  modification rather than neuroprotection, as neuroprotection 
implies direct knowledge of the effect at a cellular level. 
“Disease modification” is a more accurate term for clinical 
changes observed in a trial setting beyond that which can be 
explained by the direct symptomatic benefit.
The earliest large trial of selegiline, DATATOP, was 
undertaken with the objective of finding a disease-modifying 
therapy for PD, on the assumption that selegiline itself 
did not have symptomatic benefit in PD.13 Because the 
  investigators did not realize that selegiline would have a 
  definite   symptomatic benefit, the study design was not ade-
quate to determine whether there was a disease-modifying 
effect. This unexpected confounder “hampers a clear-cut 
detection of potentially protective actions of this monoam-
ine oxidase inhibitor”.13 A retrospective, pharmacological 
model-based analysis of the DATATOP study suggested 
a “functional protective effect of deprenyl”.50 However, 
without a new, large study with a different study design, the 
question of whether the preclinical neuroprotective effects 
of selegiline are translatable to the bedside will remain 
controversial.14
With the confounder of symptomatic therapy in mind, 
a new study design was proposed to evaluate rasagiline’s 
possible disease-modifying benefits. The study design is 
referred to as a delayed-start trial design.51 The essence 
of the delayed-start design is that of a two-arm, placebo-
controlled, double-blinded, randomized trial that has 
two phases. In phase 1, the two groups are randomized 
to active compound or placebo. In phase 2, subjects and 
investigators remain blinded to the original allocation, 
but all subjects begin active treatment. The endpoints for 
the trial design are complex, requiring that the groups are 
different at the end of phase 2, that the groups’ outcomes 
were not converging during the second phase of the trial, 
and that the outcome data were diverging during phase 
1. The study design has potential pitfalls, including, first 
and foremost, complexity, reliance on complete data from 
the first phase of the trial, and assumption that the dis-
ease progresses linearly.51 With these caveats in mind, the 
delayed-start design was used in the ADAGIO study in an 
attempt to show that rasagiline’s preclinical neuroprotec-
tive effects occur in vivo.
The results of the ADAGIO study were, unfortunately, 
controversial.52–55 The study employed the delayed-start trial 
design with two different doses of rasagiline: 1 mg and 2 mg.20 
The 1 mg dose is most commonly used in clinical practice, 
whereas the 2 mg dose showed possible   disease-modifying 
effects in a previous trial, TEMPO.18 The results of the 
ADAGIO study were mixed, with the 1 mg dose meeting all 
of the primary endpoints and the 2 mg dose failing to do so, 
presumably due to “greater symptomatic benefit”.52 However, 
the relevance of the 1 mg dose’s effect is not clear. Although 
the results for the 1 mg dose reached statistical significance, 
there is a strong argument against the clinical significance 
of the result. The difference on the T-UPDRS attributable to 
the possible disease-modifying effect of rasagiline was only 
1.7 points, which is substantially less than the 4.3 needed 
for a patient to notice a minimal CID.11 The ADAGIO study 
authors’ final conclusion was: “We cannot definitively con-
clude that rasagiline at a dose of 1 mg per day has disease-
modifying effects. It will be important to determine whether 
these results can be confirmed and whether benefits seen at 
18 months will endure and translate into reduced cumulative 
disability”.20
There is a possibility that the benefits of early   treatment 
with rasagiline will accumulate and provide a more 
  meaningful difference over years of treatment, but based on 
current evidence, rasagiline cannot be said to definitively 
have a disease-modifying effect.53,56Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Safety of MAO-B inhibitors
Adverse effects
The safety profile of the MAO-B inhibitors, in general, is 
favorable. They are generally well tolerated with few serious 
side effects, but there are a number of theoretical adverse 
reactions and interactions.57 Typical side effects of treatment 
with selegiline include dry mouth, anxiety, sleep   disturbances, 
confusion, nausea, dizziness,   orthostatic hypotension, and 
hallucinations.58–61 When used in   combination with levodopa 
in advanced PD,   selegiline may cause   dyskinesia and is more 
likely to cause   orthostatic   hypotension. Elevated liver func-
tion tests have been reported but are rare enough that regular 
monitoring of liver   function is not performed in clinical prac-
tice.61 Selegiline is   metabolized to amphetamines, which may 
be   cardiotoxic.62 Zydis   selegiline, an orally dissolving tablet, 
does not produce the same level of amphetamine metabolites 
as conventional   selegiline, but the clinical significance of 
this is unknown.17
Rasagiline, like selegiline, is well tolerated. In fact, in the 
TEMPO study, which enrolled patients with early PD, side 
effects occurred at the same rate in the active treatment and 
placebo arms. The most common side effects were headache, 
infection, dizziness, nausea, and pain.18 Rasagiline appears to 
be quite safe for elderly patients (aged .70 years) as well, 
which is an important consideration given that the incidence 
of PD increases with age.63 In patients with advanced PD, 
side effects may be more common. In the PRESTO study, 
rasagiline was more likely than placebo to cause vomiting, 
weight loss, anorexia, and balance difficulties.27 Treatment 
discontinuation due to adverse events has been low in all of 
the large, randomized trials of rasagiline.64
Hypertensive crisis
A theoretical risk of treatment with MAO inhibitors is the 
so-called “cheese effect” or tyramine effect, which can 
lead to hypertensive crisis. Hypertensive crisis may be seen 
when patients treated with nonselective MAO inhibitors eat 
foods rich in tyramine, such as aged cheese and red wine.65 
MAO-A usually metabolizes tyramine, a norepinephrine 
precursor, in the intestine. However, if MAO-A is inhibited 
in sufficient amounts, then tyramine can be absorbed, leading 
to elevated levels of norepinephrine and hypertensive crisis. 
At the 10 mg dose commonly used to treat PD, selegiline is 
quite selective for MAO-B and does not lead to the “cheese 
effect”, even when directly challenged with tyramine.66,67 
Selegiline does, however, still carry a warning on its label 
regarding the “cheese effect”, because, if used at higher 
doses, it loses its selectivity and may precipitate   hypertensive 
crisis.68   Rasagiline is more selective for MAO-B than is 
selegiline, and may have a greater margin of safety if used 
above recommended dosages.69 There have been a number 
of studies examining the effects of tyramine administered 
with rasagiline, and the safety data from these trials have 
led to the removal of the “cheese effect” warning from the 
rasagiline label.69,70
Serotonin syndrome
The serotonin syndrome consists of core clinical features 
of fever, myoclonus, and altered mental status.71 Additional 
features may include hyperreflexia, diarrhea, ataxia, tremor, 
mood alteration, and shivering.72 Originally described in 
patients taking nonselective MAO inhibitors,73 it is now 
most commonly seen in patients taking more than one drug 
with serotonergic activity (often selective serotonin reuptake 
inhibitors [SSRIs] or tricyclic antidepressants in   combination 
with MAO inhibitors).74 Treatment generally consists of 
  supportive care and discontinuing the offending agent.75 
Though serotonin syndrome is potentially quite dangerous, 
there does not appear to be a serious risk of developing it 
while taking selective MAO-B at PD doses, even when 
  taking an SSRI as well. Two retrospective studies have 
failed to show evidence of serotonin syndrome in patients 
taking selegiline and an SSRI.75,76 A survey of members of 
the Parkinson Study Group found 4568 PD patients treated 
with a combination of selegiline and an SSRI. Of those, 
11 (0.24%) were found to have symptoms consistent with 
  serotonin syndrome; two (0.04%) had symptoms deemed 
to be serious.77 So the risk of serotonin syndrome with 
  selegiline appears minimal. Data on the use of rasagiline and 
SSRI in patients with PD are lacking; however, given the 
higher specificity of rasagiline for MAO-B than selegiline, 
it is unlikely that rasagiline has a high likelihood of causing 
serotonin syndrome. In at least one small study of healthy 
volunteers given escitalopram and rasagiline, there were no 
symptoms consistent with serotonin syndrome.78
Patient preference
Adherence
Adherence to a prescribed medical regimen is crucial 
to   successful treatment. Both underuse and overuse of 
  medication are problematic in PD. Overuse of medications 
is predominantly seen in patients taking dopamine agonists 
or levodopa, not MAO-B inhibitors.79–83 Underuse of PD 
  medications is more common than overuse84 and may be 
seen with any class of antiparkinsonian therapy, leading to 
  worsening bradykinesia and rigidity.85 Another   theoretical Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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concern regarding irregular adherence is that pulsatile 
dopaminergic stimulation may increase the risk of motor 
fluctuations.86,87 In the largest study to date on adherence to 
antiparkinsonian medication, there were a number of factors 
associated with adherence.85 Patients with motor   fluctuations, 
more severe disease, and worse mobility had poorer   adherence 
to prescribed regimens.88 Medications that could be taken 
once daily had significantly higher total therapy adherence, 
higher number of days of adherence, and higher adherence to 
dose timing than medications   prescribed three times per day.88 
Twice-daily dosing also held   advantages in total adherence 
and number of days of adherence when   compared with more 
complex regimens.88 Based on the   available data, MAO-B 
inhibitors with once-daily and twice-daily dosing likely have 
better patient adherence in clinical practice than medications 
that require more frequent dosing.
Quality of life
Another factor that may influence patient preference of a 
treatment regimen is QOL. Indirect data would suggest 
that MAO-B inhibitors improve QOL, as more complex 
drug regimens are associated with lower QOL.84 QOL 
assessments have only recently become standard additions 
to clinical trials in PD, in part due to the increasing focus 
on nonmotor   symptoms and other contributors to QOL in 
PD.29,89,90 Available trial data examining QOL in patients 
taking MAO-B inhibitors are mixed. Older trials of sele-
giline sometimes presumed that QOL improved based on 
a reduction in disease severity or motor fluctuations,91 but 
more recent trials have confirmed that selegiline improves 
QOL in patients with motor fluctuations.92 A predetermined 
subset of subjects enrolled in the TEMPO study (early PD) 
of rasagiline found that rasagiline improved QOL in PD. 
The analysis concluded that the effects of rasagiline are not 
fully explained by observed improvement in UPDRS and 
may represent antidepressant or other effects.93 However, 
the PRESTO study (advanced PD) on rasagiline failed to 
show any benefit in regard to QOL.27 Unlike the findings 
from PRESTO, postmarketing observational studies of 
rasagiline in advanced PD with motor fluctuations have sug-
gested that rasagiline improves QOL.94 Given the nature of 
  postmarketing, open-label studies, these findings should be 
interpreted with caution.
Conclusion
The use of MAO-B inhibitors for the symptomatic treatment 
of PD is widespread. In early PD, these medications are safe 
and very well tolerated, though their efficacy is only modest. 
Although theoretical concerns exist   regarding   serious adverse 
events such as serotonin syndrome and hypertensive crisis, 
these problems are very unlikely to occur if the MAO-B inhibi-
tors are used as recommended. Beyond their   symptomatic ben-
efits for PD, there is a   possibility that MAO-B inhibitors have 
a disease-modifying effect. This remains a controversial topic, 
and it is left up to the   individual clinician to decide whether 
or not to prescribe the drug with disease modification as the 
goal. Patient   adherence is another important factor that impacts 
outcomes in PD treatment. Because of their simple dosing 
schedules, MAO-B inhibitors are more likely to be accepted 
by patients and taken as   prescribed than other dopaminergic 
agents with more complex dosing schedules. At least partly 
through their symptomatic amelioration of PD symptoms, 
MAO-B   inhibitors are also likely to improve QOL in PD.
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